# Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy

> **NCT03205033** · PHASE2 · COMPLETED · sponsor: **Hospital de Clinicas de Porto Alegre** · enrollment: 36 (actual)

## Conditions studied

- Sleep Disorders, Circadian Rhythm
- Depression
- Genotoxicity
- Pain

## Interventions

- **DRUG:** Melatonin 20 MG Oral Capsule
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03205033
- **Lead sponsor:** Hospital de Clinicas de Porto Alegre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03205033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03205033, "Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03205033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*